ClinicalTrials.gg
RecruitingNCT07616297REBOOTUpdated Jun 1, 2026

Higher Radiation Dose to the Tumor May Help Avoid Surgery in Rectal Cancer Patients

An interventional study of Simultaneous integrated boost to the tumor and positive mesorectal lymph nodes in Rectal Cancer and Radiation Oncology, sponsored by Claudia Schuurhuizen. Recruiting at 1 site in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-01.

Sponsored by Claudia Schuurhuizen · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2026; still recruiting 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
25
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 74 studies in Rectal Neoplasms with a site in Netherlands — 21 open to participants now, 32 under way, 8 of them phase 3. Rectal Neoplasms · Netherlands.

Planned enrollment
51st of 59
25 · median 108
Started
2026
with 3 others
No phase
16 of 74
5 open now
Primary completion
2029-08
later than 27 of 31 live
Registered
71st of 74
by date

Among the 74 studies in Rectal Neoplasms with a site in Netherlands, this one is the 51st largest by planned enrollment of the 59 interventional ones that give a count, is one of 4 that started in 2026, is one of 16 with no phase, reaches primary completion later than 27 of the 31 other live ones, and was the 71st registered.

Rectal Neoplasms

2,404 studies on the registry are indexed under Rectal Neoplasms; 588 are open to participants now.

Browse Rectal Neoplasms studies →

Open to participants now

21 of the 74 studies in Rectal Neoplasms with a site in Netherlands are open now. Recruiting first, the newest first:

15 more — sign in →

All 21 open studies →

A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →

Who these studies take

Of the 404 Rectal Neoplasms studies recruiting now, 209 (52%) set no upper age limit and 143 (35%) stop at 75 or younger; 19 take children under 18; 16 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 74 studies in Rectal Neoplasms with a site in Netherlands, or all of them as a file.
02

Study summary

The goal of this prospective study is to evaluate if a higher radiation dose to the tumor can increase the organ preservation rate in non-locally advanced rectal cancer.

Read the detailed description

Rationale:

Organ preservation has emerged as a promising alternative to total mesorectal excision (TME) for non-locally advanced rectal cancer, aiming to reduce long-term functional impairments and improve quality of life. While magnetic resonance (MR)-guided radiotherapy boosts have shown potential in enhancing organ preservation rates, their high costs, prolonged treatment times and limited accessibility prevent widespread adoption. To address this gap in current treatment options, this study investigates a more accessible online adaptive boost strategy based on cone-beam computed tomography (CBCT) imaging, with the aim of expanding organ-preserving treatment options for rectal cancer patients.

Objective:

The primary objective of this study is to evaluate the organ preservation rate at two-year follow-up in patients with non-locally advanced rectal cancer. Secondary objectives include the assessment of clinical and pathological response rates, recurrence and survival outcomes, biological effects, treatment-related toxicities, bowel function, quality of life, tumor regression, CBCT-based workflow, and target and organ motion during treatment.

Study design:

This study is designed as a non-randomized, single arm, monocenter, phase II clinical trial.

Study population:

Patients (n=25) older than 18 years with non-locally advanced rectal cancer (defined as cT1-3N0-IM0) and a wish for organ preservation, who are referred for treatment.

Intervention (if applicable):

Addition of a simultaneous integrated boost (SIB) to the standard chemoradiotherapy (CRT) scheme of 2.0 Gy to the mesorectum. The radiotherapy scheme consists of 25 fractions, delivering 2.0 Gy per fraction to the mesorectum and 2.4 Gy per fraction to the tumor and positive mesorectal lymph nodes.

Main study parameters/endpoints:

This study aims to demonstrate that the investigated treatment approach results in an increased organ preservation rate of 70% at two year follow-up compared to historical data.

Nature and extent of the burden and risks associated with participation, benefit and group relatedness:

Preclinical data confirmed the feasibility of the investigated SIB-CRT approach, demonstrating limited and clinically acceptable increases in organ at risk doses compared to the standard CRT scheme, all remaining well within clinical constraints. Furthermore, current literature supports the safety of dose escalation CRT strategies for rectal cancer, reporting manageable acute toxicity profiles, with symptoms typically returning to baseline after treatment. Based on these data, the investigated SIB-CRT strategy is expected to result in only minimal additional toxicities compared to standard CRT therapy.

The additional burden for the participants includes five MRI scans (approximately five hours total), scheduled alongside routine visits to minimize inconvenience. Patients will also be asked to complete three questionnaires at five time points, requiring approximately two hours in total, and to provide one additional 20 mL blood sample during three routine blood withdrawals.

The principal investigators consider the additional potential risk and burden for patients in the study to be acceptable. This study aims to significantly improve organ preservation rates, offering a meaningful benefit to individual patients by potentially avoiding TME surgery.

03

Conditions studied

  • Rectal Cancer
  • Radiation Oncology

Browse trials for

Keywords

  • Radiation Oncology
  • Rectal cancer
  • Organ Preservation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years
  • (ECOG) performance status ≤2
  • confirmed rectal adenocarcinoma
  • Non-locally advanced rectal cancer, defined as (magnetic resonance imaging (MRI)-based) T1-3, N0/N1 (≤3 positive mesorectal lymph nodes), MX/M0
  • Indication for curative treatment with organ preservation
  • Discussed in the multidisciplinary tumor board (MTB)
  • Written

Exclusion criteria

Exclusion Criteria:

  • Previous radiotherapy in the pelvic area
  • Other , except for adequately treated basal cell carcinoma (BCC), at time of inclusion or within 3 years prior to inclusion
  • for (chemo)radiotherapy or surgery
  • Presence of lateral lymph nodes, cN2 status, extramural vascular invasion (EMVI) or mesorectal fascia involvement as seen on MRI
  • Mucinous defined tumor on MRI
  • Prior local excision of the primary tumor
  • DPD (dihydropyrimidine dehydrogenase) deficiency
  • Unable to understand the requirements of the study and to give written , as determined by the treating physician
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
25 participants (estimated)

Study arms

  • Experimental
    Simultaneous integrated boost

    Treatment arm, in which all participating patients will receive the simultaneous integrated boost (SIB)

    Radiation: Simultaneous integrated boost to the tumor and positive mesorectal lymph nodes

Interventions

  • RadiationSimultaneous integrated boost to the tumor and positive mesorectal lymph nodes

    Addition of a simultaneous integrated boost (SIB) to the standard chemoradiotherapy (CRT) scheme of 2.0 Gy to the mesorectum. The radiotherapy scheme consists of 25 fractions, delivering 2.0 Gy per fraction to the mesorectum and 2.4 Gy per fraction to the tumor and positive mesorectal lymph nodes.

06

What researchers measure

Primary outcomes

  1. Organ preservation

    Organ preservation is considered unsuccessful if the rectum is surgically removed, a stoma is present, or a non-salvageable locoregional cancer recurrence is developed.

    Time frame: During two-year follow-up

Secondary outcomes

  1. Rate of clinical complete response

    Defined as the proportion of patients showing complete resolution of the tumor, assessed through endoscopy and MRI

    Time frame: Assessed at the two response assessments (14-16 weeks and 26 weeks after the start of treatment)

  2. Rate of pathological complete response

    Evaluated in patients undergoing surgical resection who did not achieve cCR. pCR is defined as the absence of any residual tumor in surgical specimens, assessed via histopathological examination.

    Time frame: During two-year follow-up

  3. Local progression-free survival

    Defined as the absence of tumor regrowth at or near the primary tumor site. Assessed through clinical evaluation and radiological imaging during the follow-up period.

    Time frame: During two-year follow-up

  4. Distant progression-free survival

    Defined as the absence of distant metastasis or death from any cause. Monitored with regular imaging and clinical evaluations during the follow-up period.

    Time frame: During three-year follow-up

  5. Overall survival

    Defined as the time from the start of treatment to death from any cause.

    Time frame: During three-year follow-up

  6. Biological effect of the treatment

    Blood analyses to assess circulating tumor DNA (ctDNA) as a potential biomarker to predict treatment response.

    Time frame: An additional 20 mL blood sample will be collected during scheduled blood withdrawal moments at three time points: (1) at baseline, (2) 2 weeks after start of treatment, and (3) 14-16 weeks after start of treatment.

  7. Toxicities

    Acute and late toxicities will be evaluated using the Common Terminology Criteria for Adverse Events (CTCAE) version 6.0. Both patient- and clinician-reported toxicity will be assessed during regular follow-up visits. Toxicities will be scored using the CTCAE scale, which ranges from Grade 0 (no toxicity) to Grade 5 (death), with higher grades indicating more severe adverse outcomes.

    Time frame: During two-year follow-up

  8. Bowel function

    Evaluated using the low anterior resection syndrome (LARS) score, completed by the patient through a self-administered questionnaire. by a questionnaire which the patient fills in by themself. The total score ranges from 0 to 42 points, with higher scores indicating more severe symptoms. The following categories are used: 0-20 points: No LARS, 21-29 points: Minor LARS, 30-42 points: Major LARS

    Time frame: Baseline and 3, 6, 12 and 24 months after start of treatment

  9. Quality of Life (QoL)

    Measured using the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 questionnaire, filled in by the patient. All of the scales and single-item measures range in score from 0 to 100. A high score for the functional scale and functional single-items represents a high or healthy level of functioning. A high score for the global health status/QoL scale represents a high QoL, whereas a high score for the symptom scale and single items represents a high level of symptomatology or problems.

    Time frame: Baseline and 3, 6, 12 and 24 months after start of treatment

  10. Quality of Life (QoL)

    Measured using the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-CR29 questionnaire, filled in by the patient. All of the scales and single-item measures range in score from 0 to 100. A high score for the functional scale and functional single-items represents a high or healthy level of functioning, whereas a high score for the symptom scales and single-items represents a high level of symptomatology or problems.

    Time frame: Baseline and 3, 6, 12 and 24 months after start of treatment

  11. Tumor regression during treatment, monitored through weekly MRI scans

    Weekly information to evaluate tumor regression during treatment. This includes five MRI scans in total, each requiring approximately one hour, including waiting time. Retrospectively, these scans will also be used to assess inter- and intrafractional motion of the target and OARs to investigate the potential for further margin reduction.

    Time frame: Baseline, and treatment week 2, 3, 4 and 5

  12. Target and organ intra- and interfraction motion

    Daily CBCT scans acquired pre-, intra-, and post-treatment will be retrospectively analyzed to assess inter- and intrafractional motion of the target and OARs to investigate the potential for further margin reduction in millimeters.

    Time frame: CBCT data is gathered daily as standard-of-care during the 5-week treatment

  13. Feasibility of the CBCT-based SIB online adaptive workflow

    Feasibility of the CBCT-based SIB online adaptive workflow including treatment time in minutes will be evaluated using treatment logs.

    Time frame: During the 5-week treatment course

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Aug 2029, 42 months after the start.

Of 329 non-industry interventional studies with no phase under Rectal Neoplasms, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 78. This study's planned 42 months is below that.

Counting every sponsor, half of 336 studies reached it within 51 months; a quarter within 23 and three quarters within 78.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 13, 2026
First posted
Jun 1, 2026
StartActual
Jan 27, 2026
Primary completionEst.
Aug 1, 2029
CompletionEst.
Aug 1, 2030
Last update
Jun 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07616297
Lead sponsor
Claudia Schuurhuizen
Responsible party
Claudia Schuurhuizen (Principal Investigator, Erasmus Medical Center) — Sponsor-investigator
First posted
Jun 1, 2026
Start date
Jan 27, 2026
Primary completion
Aug 1, 2029 (estimated)
Completion
Aug 1, 2030 (estimated)
Last update
Jun 1, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion